The Experts below are selected from a list of 198 Experts worldwide ranked by ideXlab platform
David J Schembri Wismayer - One of the best experts on this subject based on the ideXlab platform.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Case report and literature review This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:Objective: We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Study Design: Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Methods: Case report and literature review Results: This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. Conclusions: We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.
Michelle M Roeser - One of the best experts on this subject based on the ideXlab platform.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Case report and literature review This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:Objective: We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Study Design: Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Methods: Case report and literature review Results: This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. Conclusions: We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.
William C. Perry - One of the best experts on this subject based on the ideXlab platform.
-
P236 Tonsil Carcinoma Treated by Transoral Laser Microsurgery, I: Previously Untreated Tumors
Archives of Otolaryngology–Head & Neck Surgery, 2006Co-Authors: Michael L. Hinni, David G. Grant, John R. Salassa, Bruce W. Pearson, William C. PerryAbstract:whether Id1 regulates angiogenesis in HNSCC. Design: Human HNSCC tissue specimens were procured for examination of the coexpression of Id1 and CD31 (an endothelial cell marker). An HNSCC cell line (CA9-22) and a nontumorigenous keratinocyte cell line (Rhek-1A) were transfected with Id1 and harvested for evaluation of vascular endothelial growth factor (VEGF) and interleukin8(IL-8)promoter activities. Inaddition,humanumbilical vein endothelial cells (HUVEC) were transfected with Id1 for evaluation of cell proliferation by 5-bromo2 -deoxyuridine incorporation and cell counts. Results: In vivo, Id1 was coexpressed with CD31 in the human HNSCC tissue specimens as shown by doublelabeling immunohistochemical analysis. In vitro, Id1 transfection in CA9-22 and Rhek-1A cells significantly increased the promoter activities of both VEGF and IL-8. Id1 transfection in HUVEC increased the cell proliferation. Conclusions: Id1 plays a role in the angiogenesis of HNSCC via regulation of VEGF and IL-8.
-
P237 Tonsil Carcinoma Treated by Transoral Laser Microsurgery, II: Persistent, Recurrent, and Second Primary Tumors
Archives of Otolaryngology–Head & Neck Surgery, 2006Co-Authors: David G. Grant, Michael L. Hinni, John R. Salassa, Bruce W. Pearson, William C. PerryAbstract:whether Id1 regulates angiogenesis in HNSCC. Design: Human HNSCC tissue specimens were procured for examination of the coexpression of Id1 and CD31 (an endothelial cell marker). An HNSCC cell line (CA9-22) and a nontumorigenous keratinocyte cell line (Rhek-1A) were transfected with Id1 and harvested for evaluation of vascular endothelial growth factor (VEGF) and interleukin8(IL-8)promoter activities. Inaddition,humanumbilical vein endothelial cells (HUVEC) were transfected with Id1 for evaluation of cell proliferation by 5-bromo2 -deoxyuridine incorporation and cell counts. Results: In vivo, Id1 was coexpressed with CD31 in the human HNSCC tissue specimens as shown by doublelabeling immunohistochemical analysis. In vitro, Id1 transfection in CA9-22 and Rhek-1A cells significantly increased the promoter activities of both VEGF and IL-8. Id1 transfection in HUVEC increased the cell proliferation. Conclusions: Id1 plays a role in the angiogenesis of HNSCC via regulation of VEGF and IL-8.
Patrick Pauwels - One of the best experts on this subject based on the ideXlab platform.
-
Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell Carcinomas
BMC Cancer, 2010Co-Authors: Nancy Van Damme, Philippe Deron, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean-luc Van Laethem, Franki Speleman, Patrick Pauwels, Marc PeetersAbstract:Background With the availability of effective anti-EGFR therapies for various solid malignancies, such as non-cell small lung cancer, colorectal cancer and squamous cell Carcinoma of the head and neck, the knowledge of EGFR and K-RAS status becomes clinically important. The aim of this study was to analyse EGFR expression, EGFR gene copy number and EGFR and K-RAS mutations in two cohorts of squamous cell Carcinomas, specifically anal canal and Tonsil Carcinomas. Methods Formalin fixed, paraffin-embedded tissues from anal and Tonsil Carcinoma were used. EGFR protein expression and EGFR gene copy number were analysed by means of immunohistochemistry and fluorescence in situ hybridisation. The somatic status of the EGFR gene was investigated by PCR using primers specific for exons 18 through 21. For the K-RAS gene, PCR was performed using exon 2 specific primers. Results EGFR immunoreactivity was present in 36/43 (83.7%) of anal canal and in 20/24 (83.3%) of Tonsil squamous cell Carcinomas. EGFR amplification was absent in anal canal tumours (0/23), but could be identified in 4 of 24 Tonsil tumours. From 38 anal canal specimens, 26 specimens were successfully analysed for exon 18, 30 for exon 19, 34 for exon 20 and 30 for exon 21. No EGFR mutations were found in the investigated samples. Thirty samples were sequenced for K-RAS exon 2 and no mutation was identified. From 24 Tonsil specimens, 22 were successfully analysed for exon 18 and all 24 specimens for exon 19, 20 and 21. No EGFR mutations were found. Twenty-two samples were sequenced for K-RAS exon 2 and one mutation c.53C > A was identified. Conclusion EGFR mutations were absent from squamous cell Carcinoma of the anus and Tonsils, but EGFR protein expression was detected in the majority of the cases. EGFR amplification was seen in Tonsil but not in anal canal Carcinomas. In our investigated panel, only one mutation in the K-RAS gene of a Tonsil squamous cell Carcinoma was identified. This indicates that EGFR and K-RAS mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in anal canal and Tonsil squamous cell Carcinoma.
-
Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell Carcinomas
BMC cancer, 2010Co-Authors: Nancy Van Damme, Philippe Deron, Pieter Demetter, Alain Bols, Filip Baert, Franki Speleman, Nadine Van Roy, Jo Van Dorpe, Jean-luc Van Laethem, Patrick PauwelsAbstract:With the availability of effective anti-EGFR therapies for various solid malignancies, such as non-cell small lung cancer, colorectal cancer and squamous cell Carcinoma of the head and neck, the knowledge of EGFR and K-RAS status becomes clinically important. The aim of this study was to analyse EGFR expression, EGFR gene copy number and EGFR and K-RAS mutations in two cohorts of squamous cell Carcinomas, specifically anal canal and Tonsil Carcinomas. Formalin fixed, paraffin-embedded tissues from anal and Tonsil Carcinoma were used. EGFR protein expression and EGFR gene copy number were analysed by means of immunohistochemistry and fluorescence in situ hybridisation. The somatic status of the EGFR gene was investigated by PCR using primers specific for exons 18 through 21. For the K-RAS gene, PCR was performed using exon 2 specific primers. EGFR immunoreactivity was present in 36/43 (83.7%) of anal canal and in 20/24 (83.3%) of Tonsil squamous cell Carcinomas. EGFR amplification was absent in anal canal tumours (0/23), but could be identified in 4 of 24 Tonsil tumours. From 38 anal canal specimens, 26 specimens were successfully analysed for exon 18, 30 for exon 19, 34 for exon 20 and 30 for exon 21. No EGFR mutations were found in the investigated samples. Thirty samples were sequenced for K-RAS exon 2 and no mutation was identified. From 24 Tonsil specimens, 22 were successfully analysed for exon 18 and all 24 specimens for exon 19, 20 and 21. No EGFR mutations were found. Twenty-two samples were sequenced for K-RAS exon 2 and one mutation c.53C > A was identified. EGFR mutations were absent from squamous cell Carcinoma of the anus and Tonsils, but EGFR protein expression was detected in the majority of the cases. EGFR amplification was seen in Tonsil but not in anal canal Carcinomas. In our investigated panel, only one mutation in the K-RAS gene of a Tonsil squamous cell Carcinoma was identified. This indicates that EGFR and K-RAS mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in anal canal and Tonsil squamous cell Carcinoma.
Kerry D Olsen - One of the best experts on this subject based on the ideXlab platform.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Case report and literature review This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.
-
Synchronous bilateral Tonsil squamous cell Carcinoma.
The Laryngoscope, 2010Co-Authors: Michelle M Roeser, Eran E Alon, Kerry D Olsen, Eric J Moore, Marosh Manduch, David J Schembri WismayerAbstract:Objective: We discuss the treatment and pathology of simultaneous bilateral metastatic palatine Tonsil Carcinoma. The current literature of the diagnosis and management of unknown primary oropharyngeal neoplasms is reviewed including the role of positron emission tomography (PET) imaging. Study Design: Squamous cell Carcinoma (SCCA) of the palatine Tonsil typically presents as a unilateral mass in the oropharynx or as a mass in the ipsilateral neck indicating a lymph node involved with metastasis. The Carcinoma rarely presents with involvement of the contralateral lymph nodes, and this situation typically is present only in very advanced local disease. Simultaneous discontiguous disease involving both palatine Tonsils is exceedingly rare with less than five cases reported in the medical literature. Methods: Case report and literature review Results: This case report involves a 51 year-old male with bilateral palatine Tonsil squamous cell Carcinoma and bilateral metastatic neck disease. He presented with a left cystic neck mass diagnosed as squamous cell Carcinoma by fine needle aspiration. On exam, the site of the primary tumor was suspected to be ipsilateral Tonsil. PET scanning demonstrated asymmetric FDG activity in the contralateral palatine Tonsil and neck. The patient underwent bilateral transoral robotic-assisted partial oropharyngectomy demonstrating separate Tonsillar Carcinomas, both of which were HPV positive. Bilateral neck dissections demonstrated metastatic involvement of one right and two left cervical nodes. Conclusions: We describe an exceedingly rare case of bilateral simultaneous metastatic palatine Tonsil SCCA. This finding raises the question regarding the need for bilateral Tonsillectomy in the case of the unknown primary or proven Tonsil Carcinoma with HPV positivity.